Open Orphan Chairman Cathal Friel speaks to BRR Media re the new contract, other developments and the CEO’s departure
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Rosie Riall at BRR Media after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study. Cathal also covers the channel pipeline, the hVIVO quarantine centre, flu and malaria vaccines and the planned departure of CEO Trevor Phillips.
Open Orphan #ORPH & Cadence Minerals #KDNC on the Vox Markets podcast
Cathal Friel, Executive Chairman of Open Orphan (ORPH) talks about the major new contract they’ve signed with a US biotechnology company. Kiran Morzaria CEO of Cadence Minerals (KDNC) provides an update on operations at their Amapá project. Interview starts at 24 minutes 40 seconds. Link here to listen
Open Orphan #ORPH Exec Chairman Cathal Friel speaks to Proactive’s Andrew Scott about the new US biotech deal
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study.
Open Orphan #ORPH – Major New Contract Signed With US Biotech Company for RSV Human Study & CEO Trevor Phillips to Step Down.
Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce the signing of a new contract with a US biotechnology Company for the provision of […]
Open Orphan #ORPH: The Times – Inside Story of coronavirus battlers. The Sun – We salute the unsung key workers.
Inside stories of coronavirus battlers Aerogen, Hibergene, Open Orphan and Nearform Ireland was placed sixth last week in a list of nations ranked on their response to the Covid-19 crisis in terms of innovation. The league table was compiled by StartupBlink, a Swiss-Israeli company that collates data on start-ups; the United Nations-backed Health Innovation Index; […]
Irish Independent – Open Orphan subsidiary starts testing drug for treating Covid-19
by Ellie Donnelly A subsidiary of Open Orphan has started testing a drug that could potentially treat Covid-19. Open Orphan is a Europe- focused pharma services company specialising in rare disease and so-called orphan drugs. The tests are being carried out by its London-based subsidiary Hvivo on behalf of its client Nearmedic International. The drug […]
Irish Times – Open Orphan to test Covid-19 drug through London subsidiary
Pharma company steps up fight against virus that has infected more than 2.6m worldwide by Ciara O’Brien Dublin-listed pharma services company Open Orphan has begun testing an anti-viral treatment for Covid-19 through its London-based subsidiary Hvivo. The testing is being carried out on behalf of Nearmedic International, a specialist pharmaceutical, biotechnological and medical company headquartered […]
Open Orphan #ORPH – Testing of anti-viral for treating COVID-19 underway
Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of […]
Open Orphan: Flu vaccine data showcased in peer reviewed article – Proactive Investors
by Ian Lyall. FLU-v has been developed by Imutex, 49%-owned by Open Orphan unit hVIVO The results of a successful phase IIb trial of a potential flu vaccine being developed by an Open Orphan PLC (LON:ORPH) joint-venture have been written up in a peer-reviewed article carried by a scientific journal. The data from FLU-v 004 […]
A view from the hVivo / Open Orphan #ORPH Laboratory – Professor John Oxford
With Marie’s help and encouragement from the scientific group and Cathal Friel, I am re starting “My View” Series which will be as before, a mixture of Science and with a personal view. Marie is very important, not least since she can read my writing after a 5-year absence. I am pleased to be back. […]